Cargando…
Complement-targeted therapy: development of C5- and C5a-targeted inhibition
The complement system is a major effector of humoral immunity and natural immunity. The complement system has three independent pathways of complement activation: a classical pathway, an alternative pathway, and a lectin pathway. These pathways converge to a common pathway that activates C3. This pa...
Autores principales: | Horiuchi, Takahiko, Tsukamoto, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725830/ https://www.ncbi.nlm.nih.gov/pubmed/29259684 http://dx.doi.org/10.1186/s41232-016-0013-6 |
Ejemplares similares
-
Complement C5 inhibition in patients with COVID- 19 - a promising target?
por: de Latour, Regis Peffault, et al.
Publicado: (2020) -
Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease
por: Trambas, Inez A., et al.
Publicado: (2023) -
Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
por: Sommerfeld, Oliver, et al.
Publicado: (2021) -
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea
por: Brocklebank, Vicky, et al.
Publicado: (2017) -
Targeting complement anaphylatoxin C5a receptor in hyperoxic lung injury in mice
por: XU, YING, et al.
Publicado: (2014)